Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 19, 2014
Pharmacy Choice - News - Pharmaceutical Development - April 19, 2014

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/18/14 - Acceleration Laboratory Earns Four out of Five CRO Leadership Awards
By a News Reporter-Staff News Editor at Drug Week Acceleration Laboratory Services Inc., a unit of Acceleration Scientific LLC, a leader in drug development and contract research, announced their acceptance of the 2014 CRO Leadership Awards from Life Science Leader magazine in the categories of Regulatory, Innovation, Productivity and Reliability
4/18/14 - Actavis Confirms Favorable Ruling in Generic Lialda Patent Suit
By a News Reporter-Staff News Editor at Health& Medicine Week Actavis plc confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda infringes United States Patent No. 6,773,720. Actavis' Abbreviated New Drug Application for its generic version of Lia
4/18/14 - BioAlliance Pharma and Topotarget to Merge [Health & Beauty Close - Up]
BioAlliance Pharma SA, a company specialized in the development of drugs within orphan oncology diseases, and Topotarget A/S, a Scandinavian-based biopharmaceutical company, have announced their intention to merge to create a leading orphan oncology company with a highly complementary pipelines of late-stage products addressing significant unmet...
4/18/14 - Boston Scientific Receives FDA Approval of New Defibrillators and Heart Failure Devices [Professional Services Close - Up]
Boston Scientific Corp. has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. These newly approved devices continue the Boston Scientific history of projected longevity and a six-year CRT-D warranty. Extending the Boston Scientific portfolio of defibrillators, the ICDs in t
4/18/14 - Certara Purchases Specialty Contract Research Organization Synchrogenix [Health & Beauty Close - Up]
Certara, a technology-enabled drug development and drug safety consultancy, announced that it has acquired specialty contract research organization Synchrogenix Information Strategies Inc.. Donald A. Deieso, Chairman of Certara, said, "Pharmaceutical companies are looking for greater value and increased synergies from their outsourcing partners.
4/18/14 - FDA approves Ragwitek for short ragweed pollen allergies
Release date- 17042014- The U.S. Food and Drug Administration today approved Ragwitek, the first allergen extract administered under the tongue to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 years through 65 years of age. 'The approval of Ragwitek offers millions of adults living with ragweed p
4/18/14 - Findings from General Hospital in the Area of Health-System Pharmacy Described
By a News Reporter-Staff News Editor at Drug Week Investigators discuss new findings in Drugs and Therapies. According to news reporting from Houston, Texas, by NewsRx editors, the research stated, "The pharmacology, pharmacokinetics, clinical efficacy, and safety of a first-in-class protein synthesis inhibitor for use in treatment-resistant chro
4/18/14 - Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Targeted Medical Pharma Completes Middle East Distribution Agreement
Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "These positive results have propelled the enrollment of the second cohort with strong participation across our clinical trial sites. In 2013, Galectin Therapeutics received Fast Track designation from the FDA for this clinical development..
4/18/14 - GSK and Genmab receive FDA approval for Arzerra (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate
Release date- 17042014- GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration has approved a Supplemental Biologic License Application for the use of Arzerra, a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic...
4/18/14 - Lannett Gets FDA Approval for Diazepam Oral Solution (Concentrate), 5 mg/mL [Health & Beauty Close - Up]
Lannett Company, Inc. said that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diazepam Oral Solution, 5 mg/ mL, a Schedule C-IV controlled drug. "We believe our ANDA for Diazepam Oral Solution, 5 mg/mL was the first bioequivalent Diazepam Oral Solution product approved by the FDA,"
4/18/14 - ProTrials Finalizes Phase III Clinical Trial for New Ophthalmic Disease Treatment [Professional Services Close - Up]
ProTrials Research, Inc., a company focusing on the clinical research organization industry, announced the completion of a large Phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease, a chronic condition affecting approximately 25 million people in the U.S. According to a release, this milestone adds
4/18/14 - Reverse Medical Corp. Gets FDA IDE Approval for BARREL Vascular Reconstruction Device [Health & Beauty Close - Up]
Reverse Medical Corp. has announced FDA IDE approval for clinical investigation of their BARREL Vascular Reconstruction Device. "FDA approval of this clinical trial represents a significant accomplishment, and we're excited to begin evaluating this promising endovascular treatment alternative for patients with limited options available today.
4/18/14 - Stephen Holcombe to Lead TransTech Pharma and High Point Pharmaceuticals [Health & Beauty Close - Up]
TransTech Pharma has announced that effective March 28, Stephen L. Holcombe, who previously served as the Company's Senior Vice President and Chief Financial Officer, has been appointed to serve as the President of TransTech and its sister company High Point Pharmaceuticals. In a release, the Company said that Holcombe will also continue his duties
4/18/14 - Tokai Pharmaceuticals Taps Karen Ferrante M.D. as Head of R&D and Chief Medical Officer [Health & Beauty Close - Up]
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focusing on developing new treatments for prostate cancer and other hormonally driven diseases, have announced the appointment of Karen J. Ferrante, M.D. as head of R&D and chief medical officer. Ferrante, formerly oncology therapeutic area head for Takeda Pharmaceuticals and the Takeda Cambr
4/18/14 - United Kingdom : GSK and Genmab receive FDA approval for Arzerra (ofatumumab) as first-line treatment in combination with chlorambucil for patients... [TendersInfo (India)]
United Kingdom: GSK and Genmab receive FDA approval for Arzerra as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia for whom f. GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration has approved a Supplemental Biologic License Application for the use of.
4/18/14 - United States : FDA approves Ragwitek for short ragweed pollen allergies [TendersInfo (India)]
The U.S. Food and Drug Administration today approved Ragwitek, the first allergen extract administered under the tongue to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 years through 65 years of age. The approval of Ragwitek offers millions of adults living with ragweed pollen allergies in the Un
4/18/14 - Vivolux Gets FDA Clearance to Proceed with Clinical Study - New Drug Candidate from Vivolux Starves Cancer Cells [Health & Beauty Close - Up]
Vivolux AB, a drug discovery company specialized in cancer treatment, announced that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company's promising projects, and which was recently published in the journal Nature Communications. The study will be conducted in collaboration with Mayo Clini
4/17/14 - "Devices and Methods for Stimulation of Hair Growth" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventors Verner Rashkovsky, Ines; Vaynberg, Boris, filed on September 25, 2012, was made available online on April 3, 2014, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application has not be
4/17/14 - Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation [Global Data Point]
Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New Drug Application beginning on April 1, 2015.&# x0D;. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Actavis remains i
4/17/14 - Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration of AG-348 in a Phase 1 study in healthy volunteers. Today s announcement marks the initiation of our first clinical program in IEMs and our third as a company, said David Schenkein, M.D., chief execu
4/17/14 - ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK(r)
Licensed to Merck for North America by ALK, RAGWITEK (r) is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Jens Bager, ALK's President and
4/17/14 - ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK
Licensed to Merck for North America by ALK, RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Jens Bager, ALK s President a
4/17/14 - Ansell Capital Corp. Announces Proposed Reverse Takeover Transaction With BriaCell Therapeutics Corp.
Ansell Capital Corp. is extremely pleased to announce that it has entered into a binding letter of intent for the arm's length acquisition of 100% of the issued and outstanding common shares of BriaCell Therapeutics Corp., a private cancer immunotherapy company incorporated under the laws of the State of Delaware with its head office in Los Angeles
4/17/14 - ARCA biopharma Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2 B/3 adaptive design clinical trial. Michael R. Bristow, President and CEO, ARCA biopharma, Inc. Dr. Michael R. Bristow, President and
4/17/14 - BioAlliance Pharma Reports a New Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag in Primary Liver Cancer [Manufacturing Close - Up]
BioAlliance Pharma SA, a Company specializing in the development of drugs in orphan oncology diseases, announced that the European Independent Board of Experts, in charge of the safety profile of the ReLive Phase III trial, held its fourth meeting and once more unanimously recommended continuing the study without modification. As of today, about 40
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415